EXINI Diagnostics AB
EXINI: Success for BSI at large congress on urological cancer
EXINI Diagnostics AB 25.11.2013 14:09 --------------------------------------------------------------------------- Lund, Sweden, 2013-11-25 14:09 CET (GLOBE NEWSWIRE) -- EXINI's new website bonescanindex.org created considerable interest at EMUC (European Multidisciplinary Meeting on Urological Cancer) in Marseille. At the same congress a BSI-poster was awarded. The large international congress EMUC (European Multidisciplinary Meeting on Urological Cancer) 15-17 November 2013 brought together around 800 experts in prostate cancer and other urological cancers. EXINI attended the congress and informed about Bone Scan Index (BSI) and the software analyzing this imaging biomarker EXINI boneBSI. The new website, www.bonescanindex.org, was also launched. The website contains all the available documentation and knowledge about BSI, and attracted great interest among the clinicians as an easy way to get comprehensive information within the area. The poster exhibition at the congress presented an abstract regarding BSI study with EXINI boneBSI, 'Prognostic Value of Bone Scan Index in Patients with Prostate Cancer receiving Androgen Deprivation Therapy' by M. Reza et al, Department of Clinical Sciences Malmö and Theoretical physics, Lund University, Sweden. This presentation got a great appreciation and was awarded as the third best poster at the congress, in competition with a total of 126 contestants. 'I am very pleased to witness the strong interest among clinicians about the Bone Scan Index (BSI) and our software EXINI boneBSI. The fact that an abstract about a BSI study wins third prize for best poster, also shows that our investment in EXINI boneBSI and its biomarker are the right track' says Magnus Aurell, CEO EXINI Diagnostics AB. For more information, please contact: Magnus Aurell, CEO Phone: +46 46 286 54 25 E-mail: magnus.aurell@exini.com About EXINI Diagnostics AB (publ) EXINI Diagnostics AB (publ) offers advanced solutions for medical decision support to hospitals worldwide. The system is based on advanced image analysis by artificial intelligence and can make its own interpretation of medical images and provide diagnostic suggestions. In this way the system is used as a decision support for the diagnosing doctor. EXINI is working with products for the diagnosis of some of the most frequent endemic diseases such as coronary heart disease, cancer, dementia and Parkinson's disease. The company was founded in 1999 by Professor Lars Edenbrandt. EXINI is listed on the stock market NASDAQ OMX First North and has about 500 shareholders. Principal owner is Bo Håkansson. Thenberg & Kinde Fondkomission AB acts as Certified Adviser. ________________________________________________________________________ EXINI Diagnostics AB, Ideon Science Park, Scheelevägen 27, SE-223 70 Lund, Sweden Phone: +46 46 286 54 20, Fax: +46 46 286 54 29, info@exini.com, www.exini.com News Source: NASDAQ OMX 25.11.2013 Dissemination of a Corporate News, transmitted by DGAP - a company of EQS Group AG. The issuer is solely responsible for the content of this announcement. DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: EXINI Diagnostics AB Sweden Phone: Fax: E-mail: Internet: ISIN: SE0001810284 WKN: End of Announcement DGAP News-Service ---------------------------------------------------------------------------
Aktuelle News
Aktuelle Berichte
Keine Berichte gefunden
Anstehende Events
Keine Events gefunden
Webcasts
Keine Webcasts gefunden